FindTrial
Sign In

Role of NGAL in Vitiligo

Role of Serum NGAL Inearly Detection of CVR in Patients With Vitiligo

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05290077
Enrollment
90
Registered
2022-03-22
Start date
2022-12-15
Completion date
2022-12-15
Last updated
2022-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Keywords

NGAL & CVR

Brief summary

Role of serum Neutrophil Gelatinase-associated Lipocalin in early detection of cardiovascular risk in patients with Vitiligo

Interventions

DIAGNOSTIC_TESTNGAL

Serum NGAL in blood for early detection of CVR

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* patients with vitiligo above 20y

Exclusion criteria

* patients with systemic disease Pregnants female Lactating females Patients less than 20 y Patients with active lesions

Design outcomes

Primary

MeasureTime frameDescription
serum Neutrophil Gelatinase-associated Lipocalin in patients with Vitilig6 monthsRole of serum Neutrophil Gelatinase-associated Lipocalin in early detection of cardiovascular risk in patients with Vitiligo

Countries

Egypt

Contacts

Primary ContactDoaa G Hafez, resident
Doaag63@yahoo.com01062472611
Backup ContactMarwa M Abd El-Meged, professor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026